| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma M Krauthammer, Y Kong, BH Ha, P Evans, A Bacchiocchi, JP McCusker, ... Nature genetics 44 (9), 1006-1014, 2012 | 1324 | 2012 |
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling N Wagle, C Emery, MF Berger, MJ Davis, A Sawyer, P Pochanard, ... Journal of clinical oncology 29 (22), 3085, 2011 | 1193 | 2011 |
| The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer MM Pomerantz, N Ahmadiyeh, L Jia, P Herman, MP Verzi, ... Nature genetics 41 (8), 882-884, 2009 | 786 | 2009 |
| High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing N Wagle, MF Berger, MJ Davis, B Blumenstiel, M DeFelice, P Pochanard, ... Cancer discovery 2 (1), 82-93, 2012 | 625 | 2012 |
| 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC N Ahmadiyeh, MM Pomerantz, C Grisanzio, P Herman, L Jia, V Almendro, ... Proceedings of the National academy of sciences 107 (21), 9742-9746, 2010 | 442 | 2010 |
| Profiling critical cancer gene mutations in clinical tumor samples LE MacConaill, CD Campbell, SM Kehoe, AJ Bass, C Hatton, L Niu, ... PloS one 4 (11), e7887, 2009 | 366 | 2009 |
| Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification B Bulik-Sullivan, J Busby, CD Palmer, MJ Davis, T Murphy, A Clark, ... Nature biotechnology 37 (1), 55-63, 2019 | 260 | 2019 |
| RAC1P29S is a spontaneously activating cancer-associated GTPase MJ Davis, BH Ha, EC Holman, R Halaban, J Schlessinger, TJ Boggon Proceedings of the National Academy of Sciences, 2013 | 194 | 2013 |
| Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate BH Ha, MJ Davis, C Chen, HJ Lou, J Gao, R Zhang, M Krauthammer, ... Proceedings of the National Academy of Sciences 109 (40), 16107-16112, 2012 | 107 | 2012 |
| High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2: 82–93. doi: 10.1158 … N Wagle, MF Berger, MJ Davis, B Blumenstiel, M Defelice, P Pochanard, ... PLoS One 10 (7), e0127353, 2012 | 82 | 2012 |
| Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results CD Palmer, AR Rappaport, MJ Davis, MG Hart, CD Scallan, SJ Hong, ... Nature medicine 28 (8), 1619-1629, 2022 | 78 | 2022 |
| The genesis of Zelboraf: Targeting mutant B-Raf in melanoma MJ Davis, J Schlessinger Journal of Cell Biology 199 (1), 15-19, 2012 | 14 | 2012 |
| Identification of neoantigens with mhc class ii model TF Boucher, B Bulik-Sullivan, J Busby, MD Cao, MJ Davis, LE Young, ... US Patent App. 17/436,367, 2022 | 4 | 2022 |
| Neoantigen Identification for T-Cell Therapy R Yelensky, B Bulik-Sullivan, J Busby, MJ Davis, LE Young, JM Francis, ... US Patent App. 16/644,934, 2020 | 2 | 2020 |
| 659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases D Rasco, E Dumbrava, M Sharma, D Shepard, D Vaena, G Fleming, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| Tumor genomic profiling of FFPE samples by massively parallel sequencing. N Wagle, MF Berger, MJ Davis, B Blumenstiel, M DeFelice, WC Hahn, ... Journal of Clinical Oncology 29 (15_suppl), 10502-10502, 2011 | 1 | 2011 |
| Disease Monitoring with a Comprehensive Liquid Biopsy Assay for Patients Receiving Individualized Neoantigen Vaccine D Schenk, O Spiro, R Zhou, A Mantilla, A Ferguson, A Dhanik, K Jooss, ... JOURNAL OF MOLECULAR DIAGNOSTICS 24 (10), S108-S108, 2022 | | 2022 |
| Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients D Schenck, R Zhou, A Mantilla, O Spiro, T Patch, A Johnson, DN Gomez, ... Cancer Research 82 (12_Supplement), 1238-1238, 2022 | | 2022 |
| Selection of t cell receptors MJ Davis, JM Francis, A Jalloh, K Jooss, CD Palmer, M Skoberne US Patent App. 17/433,817, 2022 | | 2022 |
| Neoantigen identification for t-cell therapy R Yelensky, B Bulik-Sullivan, J Busby, MJ Davis, LE Young, JM Francis, ... | | 2021 |
Levi GarrawayAssociate Professor of Medicine, Harvard Medical SchoolVerifierad e-postadress på dfci.harvard.edu
